The abstract is read at the publisher; the summary is JClub's.
Postsurgical ctDNA-defined MRD positivity after upfront resection of colorectal liver metastases is linked to worse DFS (HR 4.14) and OS (HR 9.13).
- Why it matters: Adjuvant chemotherapy after curative resection of CRLM has uncertain survival benefit, and clinicians lack a reliable way to select patients likely to benefit.
- What they did: In the CIRCULATE-Japan GALAXY prospective cohort (May 2020–July 2024), ctDNA was measured 2 to 10 weeks post-surgery and landmarked at 70 days; Cox models compared ACT versus observation by MRD status.
- The result: Among MRD-positive upfront-surgery patients, ACT improved DFS (HR 0.07) and OS (HR 0.27) versus observation, while MRD-negative patients showed no clear ACT benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access